赛升药业两股东拟减持不超963.33万股，占总股本2%

Group 1 - The core point of the news is that Beijing Saiseng Pharmaceutical Co., Ltd. announced a plan for share reduction by its major shareholders, which will not affect the company's control or governance structure [1][2] - Major shareholders Ma Li and Liu Shuqin plan to reduce their holdings by a total of up to 9.63 million shares, representing no more than 2% of the company's total share capital [1] - Ma Li currently holds 29.8468 million shares (6.2% of total shares), while Liu Shuqin holds 8.748 million shares (1.82% of total shares) [1] Group 2 - The reduction will occur between October 21, 2025, and January 20, 2026, through centralized bidding and block trading [1] - The reason for the reduction is personal funding needs, and the shares being sold were acquired prior to the company's initial public offering [1] - The reduction price will be determined based on market conditions at the time of sale, with a minimum price set at the initial public offering price [1]